NCT00309725View on ClinicalTrials.gov

A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.

PHASE3CompletedINTERVENTIONAL

Enrollment

139

Participants

Timeline

Start Date

Not specified

Study Completion Date

October 31, 1999

Conditions

Alzheimer's Disease

Interventions

DRUG

galantamine

All Listed Sponsors

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00309725 - A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease. | Biotech Hunter | Biotech Hunter